When was Lantheus founded?

Lantheus was founded in 2008 and raised its 1st funding round 3 years after it was founded.

Where is Lantheus located?

Lantheus is headquartered in Billerica, United States.

How many employees does Lantheus have?

As of Aug 31, 2026, the latest employee count at Lantheus is 1291.

Is Lantheus a funded company?

Lantheus is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 29, 2011.

When was the latest funding round of Lantheus?

Lantheus' latest funding was a $***** Grant (prize money) round on Jun 19, 2012, with participation from 0 investor.

What is the annual revenue of Lantheus?

Annual revenue of Lantheus is between $100M and $500M as on Dec 31, 2014

Where does Lantheus rank among its competitors?

Lantheus ranks 254th amongst 3071 active competitors, of which 973 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Lantheus?

Lantheus' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Lantheus - 2026 Company Profile, Team, Funding, Competitors & Financials

Q: Is Lantheus an acquired company?

Lantheus got acquired by Curium on Aug 04, 2026.

Lantheus is an acquired company based in Billerica (United States), founded in 2008. It operates as a Developer of diagnostic imaging agents and targeted therapeutics. Lantheus has raised an undisclosed amount in funding. The company has 3071 active competitors, including 973 funded and 654 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of diagnostic imaging agents and targeted therapeutics. The company's lead candidate is PNT2002 a small molecule PSMA-targeted 177Lu-based radioligand therapy for metastatic castration-resistant prostate cancer. It also offers software like DEFINITY, VIALMIX, PINSYNC, TechneLite, and more. It offers imaging agents that assist in the diagnosis of heart and vascular diseases with nuclear imaging, echocardiography, and magnetic resonance imaging (MRI) technologies.

Website: www.lantheus.com/
Social
Part Of

Key Metrics

Founded Year

2008

Location

Billerica, United States

Stage

Acquired

Latest Funding Round

Grant (prize money), Jun 19, 2012, $*****

Investors

HealthCare Royalty Partners & 1 more

Ranked

254^th among 3071 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2014

Employee Count

1,291 as on Aug 31, 2026

Investment & Acquisitions

Evergreen Theragnostics & 5 more

Similar Companies

HeartFlow & 738 more

Exit Details

Acquired by Curium (Aug 04, 2026)

View Lantheus' full profile

Lantheus is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Progenics Pharmaceuticals Inc CIN: 835887 , United States, Active		$10M - $50M (As on Dec 31, 2019)	-	-
LANTHEUS HOLDINGS, INC. CIN: 35-2318913 , United States, Active	Sep 17, 1999	-	834 (As on Dec 31, 2023)	-
Lantheus CIN: 51-0396366 , United States, Active	Dec 31, 2007	-	519 (As on Jan 31, 2021)	-
LANTHEUS MEDICAL IMAGING, INC. CIN: 1500157 , United States, Active	Sep 16, 1999	$100M - $500M (As on Dec 31, 2014)	589 (As on Dec 31, 2021)	-

Lantheus got acquired by Curium on Aug 04, 2026 at an acquisition amount of $*****.

Click here to take a look at Lantheus's acquisition in detail

Lantheus has raised funding over 2 rounds. Its first funding round was on Apr 29, 2011. Lantheus has 2 institutional investors.

Here is the list of recent funding rounds of Lantheus:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 19, 2012	5603144	Grant (prize money)	4325069	9941653	9300767	3823072
Apr 29, 2011	2720510	Grant (prize money)	3734050	6435795	7835155	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Lantheus's funding rounds and investors

Lantheus' employee count trend

Lantheus has 1,291 employees as of Aug 26. Here is Lantheus's employee count trend over the years:

Uncover Lantheus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lantheus include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Lantheus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
254th	Lantheus 2008, Billerica (United States), Acquired	Developer of diagnostic imaging agents and targeted therapeutics	-	HealthCare Royalty Partners, HHS	56/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Lantheus's competitors? Click here to see the top ones

Lantheus has made 1 investments in companies including Radiopharm Theranostics. Lantheus has also acquired 5 companies including Evergreen Theragnostics and Life Molecular Imaging.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jan 28, 2025	Acquisition	Evergreen Theragnostics	2019	Jersey City (United States)
Jan 13, 2025	Acquisition	Life Molecular Imaging	2012	Berlingerode (Germany)
Jul 31, 2024	Investments	Radiopharm Theranostics	2021	Carlton (Australia)